The University of Virginia (UVA) Cancer Center is directed by Michael J. Weber, PhD. He is assisted in this role by the Senior Leadership team comprised of: Paula M. Fracasso, MD, PhD (Deputy Director and Associate Director for Clinical Research), Jay W. Fox, PhD (Associate Director for Laboratory Research Infrastructure), Dina G. Halme, PhD (Associate Director for Research Administration), Christopher A. Moskaluk, MD, PhD (Associate Director for Translational Infrastructure), and Sarah J. Parsons, PhD (Associate Director for Laboratory Research). Members of the Senior Leadership each possess a different area of responsibility, perspective, and expertise. Together they form a strong center to the matrix that is the UVA Cancer Center. Dr. Weber and the Senior Leadership use consensus building in interacting with UVA departments and committees and with the Program Leaders to formulate priorities, develop strategic plans, and allocate resources. They provide recommendations on integrating research between the Programs, discuss collaborations and discoveries within the Programs, assist in oversight of the Shared Resources, and help identify synergies in basic and clinical research and in infrastructure. Collectively, they ensure that the allocation of resources is aligned with the strategic vision of the Cancer Center. A subset of the Senior Leadership team (Weber, Fracasso, Halme, and Parsons) meets weekly and the entire team meets monthly at the CCSG Executive Committee meeting. They provide direct counsel and recommendations to the Director based on these interactions. Final authority for decisions on behalf of the UVA Cancer Center resides with the Director.
; Funds to provide partial support for Senior Leadership enables the UVA Cancer Center to develop and implement its strategic priorities. The percent effort requested from the CCSG is a small portion of the total effort each of the leaders actually expends on Cancer Center priorities.
|Melssen, Marit; Slingluff Jr, Craig L (2017) Vaccines targeting helper T cells for cancer immunotherapy. Curr Opin Immunol 47:85-92|
|Bullock, Timothy Nj (2017) TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines. Curr Opin Immunol 47:70-77|
|Scalici, Jennifer M; Arapovic, Sanja; Saks, Erin J et al. (2017) Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC). Cancer 123:977-984|
|Shukla, Girja S; Olson, Walter C; Pero, Stephanie C et al. (2017) Vaccine-draining lymph nodes of cancer patients for generating anti-cancer antibodies. J Transl Med 15:180|
|Keim-Malpass, Jessica; Mitchell, Emma M; DeGuzman, Pamela B et al. (2017) Legislative activity related to the human papillomavirus (HPV) vaccine in the United States (2006-2015): a need for evidence-based policy. Risk Manag Healthc Policy 10:29-32|
|Mills, Anne M; Paquette, Cherie; Terzic, Tatjana et al. (2017) CK7 Immunohistochemistry as a Predictor of CIN1 Progression: A Retrospective Study of Patients From the Quadrivalent HPV Vaccine Trials. Am J Surg Pathol 41:143-152|
|Rohani, Ali; Moore, John H; Kashatus, Jennifer A et al. (2017) Label-Free Quantification of Intracellular Mitochondrial Dynamics Using Dielectrophoresis. Anal Chem 89:5757-5764|
|Wages, N A; Slingluff Jr, C L; Petroni, G R (2017) Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies. Ann Oncol 28:696-701|
|O'Brien, Carleigh A; Overall, Christopher; Konradt, Christoph et al. (2017) CD11c-Expressing Cells Affect Regulatory T Cell Behavior in the Meninges during Central Nervous System Infection. J Immunol 198:4054-4061|
|Bullock, Timothy Nj (2017) Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer. Curr Opin Immunol 45:82-88|
Showing the most recent 10 out of 472 publications